Member Info for VertizeaSun

"BP, with their unlimited resources and money have not solved this problem"

Precisely which problem are you talking about? It certainly isn't pre|CISION® because that compound has now been successfully used at least 150 times and if you suggest the management would hide and disguise any failure then you probably shouldn't be investing in Avacta in the first place.

How's Verona?

Mippet is another word for Tutankhamun.

And SC's opening words suggest they'll be looking asap at the trial results:

"There’s an incredible amount of interest in AVA6103, or FAP-EXd as we now call it, although the company’s strategy at this point is to protect this asset until we have sight of the initial human data, such is its value."

Thanks Dad.

"Richard Hughes is a genuine game changer for #AVCT."

https://x.com/MylesMcNulty/status/1940703810709590352

"fast track / accelerated approval"?

Wow. Why didn't the nineteen members of the Executive Leadership Team, the Board of Directors and the Scientific Advisory Board think of that?

He's listed third in the seven strong Executive Leadership Team. Sufficient to run a small army.

More from X and I'm guessing as an attendee:

Bloodstockstats

@bloodstockstats

·

2h

Replying to

@law70437

and

@RAH00084

RH was particularly impressive. #AVCT need c£3m to repay each CLN payments I expect RH can find investors to buy shares from Avacta to enable cash payment to Heights for next two. If flagged before payments due then SP should hold up and focus can be on exceptional science.

Third party validation....that'll do nicely!

BV.....Issued by Avacta as per usual. Same dilution but one hopes they'll be paying a premium.....as opposed to the "death spiral"

RAH

@RAH00084

Anyone in the room will tell you Richard Hughes left the audience in no doubt #AVCT will solve the CLN issue.

Very clear they have deals in the pipe line.

I hope the chair’s opening statement finds its way into print.

5:18 PM · Jul 2, 2025

·

Opti....are you sure?

According to Touk (AKA Jeremiah) you'll be lucky to double your money.

I'm assuming RAH attended the AGM but obviously I can't confirm that. Fantasy? :

RAH

@RAH00084

·

4m

Replying to

@tom_the_bomb__

The general gist of statement was deals across both 6000 indications (both separately and together) in the pipe.

Initial efficacy across both P1b indications.

Breast toxicity data is replicating what they have seen in SGC.

And Richard Hughes kicking Height’s door down.

#AVCT

A positive claim posted on X. Is it true? No idea. But we should get an answer within the next 10 or 11 working days.

RAH

@RAH00084

·

37m

Replying to

@RAH00084

Richard Hughes:

“heights is not a lot of money”

“allow me to do my job”

#AVCT has its NED.

Zero doubts a cash payment is coming after that barnstorming performance.

Exactly Codejunkie.....exactly. What on earth do you think Richard Hughes is expecting by lending his name to Avacta?

Https://www.nasdaq.com/articles/avacta-appoints-david-liebowitz-cmo

The two recent NED's and Simon Bennett are too UK-centric for the US investor base but today's appointments will fix that problem. Nasdaq can't be too far off now.

He's a busy boy.....hardly back from "North" Corfu before he legs it to Verona for the opera.

I'm assuming there's now a Plan A for the CLN problem. Will we know by the AGM or is the small print taking another few weeks.....getting ready for the Heights deadline?

This company and its shareholders deserve an RNS with £/$ signs and a few digits.